Baclofen Injection
NDC Package 70511-123-20

11-digit billing NDC: 70511012320

Package Information

Baclofen injection is indicated for use in the management of severe spasticity in adult and pediatric patients age 4 years and above. This formulation utilizes a injection delivery system. Marketed by Mala Pharmaceuticals, Inc., this product is identified by NDC 70511-123 and is authorized under FDA application ANDA210315.

Identification & Billing

NDC Package Code
70511-123-20
Package Description
1 VIAL, GLASS in 1 CARTON / 20 mL in 1 VIAL, GLASS
Product Code
11-Digit Billing Format
70511012320
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Baclofen
Non-Proprietary Name
Baclofen
Substance Name
Baclofen
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Intrathecal - Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.
Active Ingredient(s)
Usage Information
Baclofen injection is indicated for use in the management of severe spasticity in adult and pediatric patients age 4 years and above. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion of baclofen injection via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy.  Baclofen injection is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only with the Medtronic SynchroMed® II Programmable Pump or other pumps labeled for intrathecal administration of baclofen injection [see Clinical Studies (14)].Prior to implantation of a device for chronic intrathecal infusion of baclofen injection, patients must show a response to baclofen injection in a screening trial [see Dosage and Administration (2.2)].

Regulatory & Marketing

Labeler Name
Mala Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA210315
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
12-23-2020
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70511-123-20 identifies a specific commercial package of 1 vial, glass in 1 carton / 20 ml in 1 vial, glass of Baclofen, a human prescription drug labeled by Mala Pharmaceuticals, Inc.. This injection is formulated for intrathecal use and contains baclofen as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Mala Pharmaceuticals, Inc. on December 23, 2020. The current certification is valid through December 31, 2026.

How is this Mala Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70511012320. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70511-123-20
11-Digit CMS (5-4-2)
70511-0123-20

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.